Surrey-based contract development and manufacturing organisation (CDMO) NextPharma is changing hands from UK private equity house Sun European Partners to London-based CapVest Partners. The agreement, signed today, is rumoured to value the business at €200m. The transaction is waiting on standard regulatory approvals.
NextPharma is a market leader in the western European pharmaceutical CDMO space, serving a global blue-chip customer base, including seven of the top ten pharma companies. The company offers a broad range of specialised product types and therapeutic areas across multiple attractive niches. NextPharma has over 1,000 employees and operations in Germany, France, Switzerland and Austria. Sun European Partners invested in 2011.
An affiliate of Sun European Partners is to sell NextPharma, a pharmaceutical contract development and manufacturing organisation (CDMO), to funds advised by CapVest Partners (CapVest), subject to regulatory approval.